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ABSTRACT 
Background. In a number of countries, reimbursement to hospitals providing renal dialysis services is 
set according to a fixed tariff. While the cost of maintenance dialysis and transplant surgery are 
amenable to a system of fixed tariffs, patients with established renal failure commonly present with 
comorbid conditions that can lead to variations in the need for hospitalisation beyond the provision of 
renal replacement therapy.  
Methods. Patient-level cost data for incident renal replacement therapy patients in England was 
obtained as a result of linkage of the Hospital Episodes Statistics dataset to UK Renal Registry data. 
Regression models were developed to explore variations in hospital costs in relation to treatment 
modality, number of years on treatment and factors such as age and comorbidities. The final models 
were then used to predict annual costs for patients with different sets of characteristics. 
Results. Excluding the cost of renal replacement therapy itself, inpatient costs generally decreased 
with number of years on treatment for haemodialysis and transplant patients, whereas costs for 
patients receiving peritoneal dialysis remained constant. Diabetes was associated with higher mean 
annual costs for all patients irrespective of treatment modality and hospital setting. Age did not have a 
consistent effect on costs.   
Conclusions. Combining predicted hospital costs with the fixed costs of renal replacement therapy 
showed that the total cost differential for a patient continuing on dialysis rather than receiving a 
transplant is considerable following the first year of renal replacement therapy, thus reinforcing the 
longer-term economic advantage of transplantation over dialysis for the health service.  
 
 
Key words: comorbidities, dialysis, established renal failure, hospital costs, regression, 
transplantation 
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Short summary:  In this paper, we analyse patient-level cost data for patients starting renal 
replacement therapy in England in order to explore how hospitals costs vary with treatment modality, 
number of years on treatment and factors such as age and comorbidities. The results of regression 
analyses suggest that, excluding the fixed costs of renal replacement therapy, inpatient costs generally 
decreased with number of years on treatment for haemodialysis and transplant patients, whereas costs 
for patients receiving peritoneal dialysis remained constant. Diabetes was associated with higher mean 
annual costs for all patients irrespective of treatment modality and hospital setting. Age did not have a 
consistent effect on costs.   
 
4 
 
INTRODUCTION 
In an attempt to control rising costs, several countries have introduced a system of fixed 
reimbursement rates for the provision of chronic dialysis for patients with established renal failure 
(ERF) [1]. Since 2010, reimbursement to hospitals providing renal dialysis services in England has 
been set according to a national tariff under the Payment by Results (PbR) system [2]. There are plans 
to introduce a similar national tariff for kidney transplantation in the near future, with separate 
currencies being developed to capture three stages of the transplant pathway: preparation for 
transplant, the inpatient episode including the transplant procedure, and post-transplant outpatient 
activity [3]. 
While the annual cost of chronic maintenance dialysis and the cost of transplant surgery are amenable 
to fixed tariffs, patients with ERF commonly present with comorbidities such as diabetes, ischaemic 
heart disease and vascular disease, which can lead to variations in the use of healthcare resources 
beyond renal replacement therapy (RRT) itself [4]. A number of previous studies have explored 
hospitalisation rates or costs among dialysis patients, however, given the challenges of collecting 
patient-level resource use data, these studies have typically been restricted to a time horizon of one 
year or less [5-7].  
Linkage of the Hospital Episodes Statistics (HES) dataset to UK Renal Registry (UKRR) data for 
patients who started RRT for ERF in England between 2003 and 2006 provides an opportunity to 
explore hospital inpatient and outpatient costs over a number of years among both dialysis and 
transplant patients. HES captures demographic information, comorbid conditions and data on all 
inpatient and outpatient care delivered in NHS hospitals in England, including treatment specialty and 
length of stay. The UKRR reports on the demography of incident RRT patients using data provided by 
renal centres. Linkage of these two datasets enhances the variables available for analysis and provides 
an opportunity to analyse a rich data source on hospitalisations for a cohort that represents >95% of 
all patients who started RRT during a defined period in England [8].  The aim of the current study is 
to analyse the linked dataset to explore variations in inpatient and outpatient hospital costs, separately 
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from the fixed cost of RRT, and in relation to treatment modality, number of years on treatment and 
factors such as age and comorbidities.  
 
METHODS 
The linked dataset comprised patients who started dialysis or received a kidney transplant in England 
between 1 April 2003 and 31 December 2006. The date of starting RRT was taken as the index date. 
If a patient on dialysis subsequently received a transplant, this patient then became part of the incident 
transplant cohort and the date of transplant was taken as the new index date for measuring subsequent 
hospitalisations. Comorbidity information in HES was determined from discharge codes from 
hospitalisations prior to starting RRT. Comorbidities were defined using International Classification 
of Disease version 10 (ICD10) codes applying algorithms previously described in the literature [9]. 
Inpatient costs were generated by grouping hospital episodes by Healthcare Resource Group (HRG) 
and applying the relevant 2011/12 PbR tariff associated with each HRG. Costs for outpatient 
appointments were assigned according to treatment function code [10]. Hospital episodes for the 
purpose of receiving maintenance dialysis or for undergoing transplant surgery were specifically 
excluded, but hospital episodes for any other reason, including procedures such as vascular access 
surgery, were included. This is because the aim of the present analysis is to explore variations in 
hospital costs separately from the costs associated with the fixed tariffs for dialysis and transplant 
surgery.  
Linkage of the HES and UKRR datasets ended in December 2009 and therefore no further 
hospitalisation data were available beyond this point. Over the observation period, an increasing 
proportion of patients were therefore administratively censored part-way through a given year due to 
the end of data availability. The proportion of patients who were administratively censored ranged 
from 0% in year one to 47% in year six for haemodialysis patients, from 0% in year one to 38% in 
year six for peritoneal dialysis patients and from 11% in year one to 63% in year six for transplant 
patients. A comparison of patient characteristics and annual costs in the years prior to administrative 
censoring did not identify any systematic differences between those patients who had been censored 
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and those who had not. Therefore for the purposes of the current analysis, data from any year in which 
a patient was administratively censored were excluded under the assumption that these data were 
missing at random. 
Patient characteristics and hospital costs in the first year after starting RRT are summarised by 
treatment modality using percentages and mean values as appropriate. Results of significance tests are 
presented to compare mean hospital costs between groups of patients with different characteristics of 
interest. Although cost data are typically not normally distributed, sample sizes in this dataset were 
sufficiently large for the use of t-tests or ANOVA to be robust to violations of the assumption of 
normality [11, 12]. In cases of unequal variances, Satterthwaite’s approximation for standard errors 
was computed. To explore changes in hospital costs over time, mean annual costs and standard errors 
are presented by number of years on RRT.   
Multiple regression was carried out to further determine which patient and treatment characteristics 
are important predictors of hospital costs. As cost data were positively skewed with a high proportion 
of patients with zero costs in the inpatient setting in any particular year, a two-part approach to the 
regression model was taken. Logistic regression was used to predict the probability of incurring any 
costs, followed by fitting generalised linear models to predict costs in patients who had at least one 
hospital episode in a given year. The effects of comorbidities on costs were explored using two 
approaches. In the first approach, individual comorbidities were included as covariates in the 
regression model and in the second approach, only the number of comorbidities was included as a 
covariate. Initially, all variables that were available in the dataset were included in the regression 
models and a process of backward elimination was used to inform variable selection using a P-value 
threshold of 0.2 [13].  Events such as transplant, renal recovery, death, or graft failure were included 
as covariates. In addition, a new variable was created to indicate if a patient died in the first half of the 
following year in order to adequately capture increased costs in the period prior to death.  
All analyses were conducted in Stata (Version 13, Stata Corp, College Station, Texas, USA). 
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RESULTS  
Descriptive analysis 
Data on hospitalisations for 12 068 incident haemodialysis patients (Table 1a), 4 018 incident 
peritoneal dialysis patients (Table 1b) and 4 149 incident transplant patients (Table 1c) were available 
for analysis. The mean age for haemodialysis patients was 68.3 years compared with 56.0 years for 
peritoneal dialysis patients and 45.4 years for transplant patients. The two most common 
comorbidities were diabetes and hypertension and, of the nine comorbidities included in the scope of 
the analysis, the average number of comorbidities per patient at baseline was approximately 1.60 for 
haemodialysis patients, 1.26 for peritoneal dialysis patients and 1.56 for transplant patients.  
Mean costs for patients during their first year of dialysis showed differences by modality, with 
haemodialysis patients incurring higher inpatient costs and peritoneal dialysis patients incurring 
higher outpatient costs. According to bivariate analysis, the presence of most comorbidities was 
associated with higher costs in the inpatient setting, but only diabetes was associated with 
significantly higher costs in both inpatient and outpatient settings and among both haemodialysis and 
peritoneal dialysis patients. Among transplant patients, congestive heart failure, peripheral vascular 
disease, diabetes and hypertension were all associated with higher costs in both inpatient and 
outpatient settings, whereas myocardial infarction, liver disease, cerebrovascular disease and deceased 
donor transplants were associated with higher costs only in the inpatient setting.  
Table 2 summarises mean annual costs for patients receiving each type of RRT over the six years of 
available data.  Combined inpatient and outpatient costs in the first year of RRT were similar for 
haemodialysis and transplant patients, however costs for transplant patients decreased more rapidly in 
subsequent years. Peritoneal dialysis patients had lower total hospital costs compared to 
haemodialysis patients in the first year, but higher average costs in year six.  
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Multiple regression 
Bivariate analysis of year 1 costs (Tables 1a, 1b and 1c) showed that events such as death can have 
opposite effects on inpatient and outpatient costs. Therefore it was important to control for these in 
multiple regression analyses and to keep the development of models for inpatient and outpatient costs 
separate. Two-part regression models were developed to determine which patient and treatment 
characteristics are important predictors of hospital costs. The final two-part models for each treatment 
modality are provided as supplementary material (available online at http://ndt.oxfordjournals.org). 
Key findings can be summarised as follows:  
In the inpatient setting, logistic regression results (Supplementary Table 1a) showed that the 
probability of incurring any inpatient costs generally decreased as the number of years on 
haemodialysis increased. Female gender and presence of comorbidities, with the exception of liver 
disease, increased the probability of incurring inpatient costs. The effect of comorbidities on the 
probability of incurring outpatient costs for haemodialysis patients was less consistent.  
Compared to the first year on RRT, patients on peritoneal dialysis had a lower probability of incurring 
inpatient and outpatient costs in subsequent years (Supplementary Table 1b), however there was not a 
consistent trend in the probability of incurring costs over time as seen among haemodialysis patients.  
For transplant patients, logistic regression results indicated that the probability of incurring inpatient 
costs, but not outpatient costs, generally decreased over time (Supplementary Table 1c). Female 
gender and comorbidities were again associated with a higher probability of incurring inpatient costs, 
whereas living donor transplants were associated with a lower probability of incurring inpatient costs 
compared to deceased donor transplants.  
Following logistic regression, generalised linear models were fitted to model costs in the subset of 
patients who had at least one inpatient or outpatient episode in a given year (Supplementary Tables 
2a, 2b and 2c). For haemodialysis and transplant patients, inpatient costs tended to decrease as 
number of years on RRT increased, however this pattern was not seen among peritoneal dialysis 
patients. Age did not have a consistent effect on costs across hospital settings and treatment 
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modalities, however where significant differences were noted, higher age was associated with lower 
costs. Of the comorbidities, only diabetes was consistently associated with higher mean annual costs 
for all patients irrespective of treatment modality and hospital setting. 
Inpatient costs in the year of death were higher across all three RRT modalities, whereas outpatient 
costs in the year of death were lower. With the exception of the first year of the dataset, death events 
were fairly evenly distributed throughout the year, meaning that patients who died incurred 
significantly higher costs despite only being alive, on average, for approximately half of the year.  
Alternative regression models based on the total number of comorbidities as a covariate, rather than 
on the presence or absence of individual comorbidities, yielded similar results, but were associated 
with slightly higher root-mean-square errors (RMSE). The number of comorbidities had a larger 
effect on hospital costs among transplant patients than among dialysis patients.  
Application of regression models for predicting costs 
A useful application of the regression models developed here is to predict hospital costs for patients 
with a given set of characteristics over time. Applying the models that have been developed, we can 
predict and compare costs for patients with different characteristics and by treatment modality. For 
illustrative purposes, Table 3 shows predicted inpatient and outpatient costs over a period of four 
years on each of the forms of RRT for three hypothetical patients: a 25-year-old female with no 
comorbidities, a 50-year-old male with diabetes and a 65-year-old male with peripheral vascular 
disease. Table 3 also shows the fixed costs associated with national tariffs for RRT (maintenance 
haemodialysis, peritoneal dialysis or deceased heart-beating donor transplant) [10, 14]. When 
comparing combined RRT and hospital costs over the four years among the three patients on the same 
modality, costs are similar on haemodialysis and transplant, however larger variations in costs are 
seen with peritoneal dialysis (range £101 938 to £109 213), mostly attributable to differences in 
inpatient costs. In all three patient examples, total costs are highest on haemodialysis and in each case, 
are approximately four times the total costs compared with a scenario in which each of these patients 
had received a transplant from a deceased donor. 
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DISCUSSION 
Many health systems around the world are grappling with the need to contain the increasing costs of 
providing care for patients with ERF and in recent years this has led to the emergence of bundled 
payments or fixed tariffs for reimbursement to providers of dialysis services. Considerable attention 
has been focused on determining what costs should be included or excluded within a fixed rate of 
payment and there is variation between countries especially with respect to drug costs, laboratory tests 
and physician fees [1]. Less attention has been directed at characterising the magnitude of other 
hospital costs beyond the fixed tariffs for RRT that are incurred by patients with ERF. These costs can 
be considerable given the high rate of comorbidities among this patient population.  Insight into 
variable hospital costs in addition to the fixed costs of RRT is important for having an overall 
understanding of the costs of managing ERF. Linkage of the United States Renal Data System 
(USRDS) and Medicare data allows for extensive analysis of costs in relation to patient characteristics 
and treatment factors, however such data sources outside the US are limited [15].    
One-time linkage of the HES and UKRR datasets has provided a rare opportunity to analyse 
variations in hospital costs beyond RRT in a large cohort of patients with ERF in England and to 
explore changes in costs over several years, as well as in relation to treatment modality and 
comorbidities. As no attempt was made to distinguish renal-related resource use from non-renal-
related resource use, the findings presented here are most relevant for looking at incremental costs 
between inpatient and outpatient settings, or between patients receiving different forms of RRT.  
Excluding the fixed costs of RRT, our analysis showed that hospital costs were highest for all 
treatment modalities in the first year but hospital inpatient costs for both haemodialysis and transplant 
patients generally decreased with number of years on RRT, with transplant patients incurring lower 
annual costs than dialysis patients. A possible explanation for higher inpatient costs among incident 
haemodialysis patients could be access-related complications such as catheter-related infections, the 
need for catheter replacement or fistuloplasty and other forms of attention to dialysis access. In the 
UK, during the time period reflected in our analysis, a national audit showed that 69% of incident 
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haemodialysis patients commenced treatment using venous catheters [16]. For transplant patients, 
higher costs in the first year reflect the need for frequent monitoring in the post-operative phase to 
manage immunosuppression, including detection and management of complications such as new 
onset diabetes after transplant (NODAT) [17-19]. 
In the current analysis there was little evidence to suggest that hospital costs increased with age or 
number of years on RRT. In some cases, older age was in fact associated with lower costs. However, 
a pattern of increasing costs was seen with many comorbidities and it is plausible that the patients 
who remained alive for longer on RRT were on average healthier and required fewer hospitalisations. 
The possibility of unobserved confounding could not be ruled out, but we believe this highlights the 
importance of controlling for comorbidities when exploring the effect of age on costs in the ERF 
population. Outpatient costs for transplant patients were highest in the first year of RRT, but dropped 
considerably in subsequent years and fell below average outpatient costs for haemodialysis patients by 
year six. In comparison, hospital costs for patients on peritoneal dialysis remained relatively constant 
over time, except for a slight decrease in years 2 and 3. These findings challenge the commonly held 
assumption that costs increase with both age and time on RRT although caution should be exercised 
in extrapolating the findings beyond the 6-year period of our analysis. As with most retrospective 
datasets, there are several limitations to our analysis. In the HES dataset, coding practices meant that 
patients with missing comorbidity information could only be recorded as having no comorbidities, so 
the true extent of missing data was not known. However, the UKRR dataset also contained 
information on comorbidities at the start of RRT for approximately half of the patients in the sample. 
Where comorbidity data were available from both HES and UKRR data sources, concordance was 
93% [8]. This high level of concordance between two independently collected data sources increases 
our confidence that missing data on comorbidities is unlikely to be a source of systematic bias in our 
analysis. Due to the structure of our dataset, another limitation is that we were unable to explore in 
more detail the specific reasons for variations in hospital costs as this would have required a more 
granular breakdown of admission codes and procedures. In addition, the current analysis did not take 
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into account drug costs, which fall outside both the fixed tariff for RRT and the hospital 
reimbursement codes in England.  
Although differences in currency, reimbursement rates for RRT and the organisation of healthcare 
systems varies from country to country, a deeper understanding of the relationship between factors 
such as age, comorbidities, treatment modality and hospital costs is likely to cut across different 
countries with varied healthcare delivery paradigms. Looking beyond fixed tariffs for RRT, hospital 
costs make up approximately 20-25% of the overall cost of managing patients on chronic dialysis. 
Taking into account both the fixed costs of RRT and variations in hospital costs characterised in the 
current analysis, it is readily apparent that although the total costs of treating dialysis and transplant 
patients may be similar in the first year of RRT, the cost differential in subsequent years is 
considerable. This reinforces the longer-term economic advantage of transplantation over dialysis for 
the health service.  
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TABLES 
Table 1a Haemodialysis patient characteristics and mean inpatient and outpatient costs (excluding the 
costs of maintenance dialysis) during the first year of renal replacement therapy  
 
n (%) 
Mean inpatient cost (£) 
(95% CI) 
p 
Mean outpatient cost (£) 
 (95% CI) 
p 
Age group 
     <50 years  2 384 (19.8%) 7 452 (6 951 , 7 954) 0.319 1 342 (1 288 , 1 396) <0.0005 
50-64 years 2 900 (24.0%) 7 122 (6 667 , 7 577) 
 
1 340 (1 291 , 1 389) 
 65-75 years 3 911 (32.4%) 7 423 (7 032 , 7 815) 
 
1 121 (1 079 , 1 163) 
 >75 years 2 873 (23.8%) 6 934 (6 477 , 7 391) 
 
893 (844 , 942) 
 Gender 
     Male 7 478 (62.0%) 7 084 (6 797 , 7370) 0.079 1 185 (1 153 , 1 216) 0.026 
Female 4 590 (38.0%) 7 495 (7 140 , 7 850) 
 
1 128 (1 090 , 1 165) 
 Death 
     No  9 530 (79.0%) 7 087 (6 821 , 7 354) 0.009 1 309 (1 280 , 1 337) <0.0005* 
Yes 2 538 (21.0%) 7 814 (7 467 , 8 160) 
 
616 (578 , 655) 
 Transplant 
     No  11 644 (96.5%) 7 336 (7 106 , 7 566) <0.0005* 1 169 (1 145 , 1 194) 0.009 
Yes 424 (3.5%) 4 606 (4 110 , 5 103) 
 
995 (858 , 1 131) 
 Recovered renal function 
No  11 715 (97.1%) 7 270 (7 042 , 7 499) 0.127 1 178 (1 153 , 1 203) <0.0005* 
Yes 353 (2.9%) 6 241 (5 368 , 7 114) 
 
664 (544 , 785) 
 Myocardial infarction 
     No  10 120 (85.1%) 7 185 (6 939 , 7 430) 0.033 1 183 (1 157 , 1 210) 0.019 
Yes 1 774 (14.9%) 7 872 (7 302 , 8 443) 
 
1 101 (1 041 , 1 162) 
 Congestive heart failure 
No  9 630 (81.0%) 7 085 (6 827 , 7 344) <0.0005* 1 187 (1 160 , 1 214) 0.010 
Yes 2 264 (19.0%) 8 145 (7 707 , 8 585) 
 
1 105 (1 050 , 1 160) 
 Peripheral vascular disease 
No  10 285 (86.5%) 7 104 (6 859 , 7 349) <0.0005* 1 170 (1 144 , 1 196) 0.854* 
Yes 1 609 (13.5%) 8 459 (7 888 , 9 030) 
 
1 177 (1 107 , 1 248) 
 Cerebrovascular disease 
No  10 812 (90.9%) 7 241 (7 002 , 7 480) 0.205 1 180 (1 154 , 1 205) 0.034 
Yes 1 082 (9.1) 7 749 (7 089 , 8 408) 
 
1 087 (1011 , 1 164) 
 Pulmonary disease 
     No  10 293 (86.5%) 7 186 (6 937 , 7 435) 0.026 1 168 (1 142 , 1 194) 0.550* 
Yes 1 601 (13.5%) 7 938 (7 434 , 8 443) 
 
1 192 (1 118 , 1 265) 
 Liver disease 
     No  11 785 (99.1%) 7 260 (7 035 , 7 484) 0.143* 1 169 (1 145 , 1 194) 0. 180* 
Yes 109 (0.9%) 10 263 (6 233 , 14 293) 
 
1 379 (1 072 , 1 687) 
 Diabetes 
     No  7 846 (66.0%) 6 685 (6 415 , 6 956) <0.0005* 1 081 (1 051 , 1 110) <0.0005* 
Yes 4 048 (34.0%) 8 454 (8 049 , 8 858) 
 
1 346 (1 303 , 1 389) 
 Cancer 
     No  10 885 (91.5%) 7 248 (7 010 , 7 487) 0.266 1 167 (1 142 , 1 193) 0.311 
Yes 1 009 (8.5%) 7 708 (7 045 , 8 370) 
 
1 213 (1 119 , 1 307) 
 Hypertension 
     No  6 372 (53.6%) 7 525 (7 180 , 7 870) 0.024* 1 153 (1 122 , 1 184) 0.118 
Yes 5 522 (46.4%) 7 013 (6 734 , 7 291) 
 
1 192 (1 154 , 1 230) 
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*Unequal variances 
Table 1b Peritoneal dialysis patient characteristics and mean inpatient and outpatient costs (excluding 
the costs of maintenance dialysis) during the first year of renal replacement therapy 
 
n (%) 
Mean inpatient cost (£) 
(95% CI) 
p 
Mean outpatient cost (£)  
(95% CI) 
p 
Age group 
     <50 years 1 395 (34.7%) 4 874 (4 463 , 5 286) 0.003 1 712 (1 642 , 1 782) <0.0005 
50-64 years 1 217 (30.3%) 5 266 (4 825 , 5 707) 
 
1 748 (1 674 , 1 823) 
 65-75 years 967 (24.1%) 4 762 (4 267 , 5 257) 
 
1 600 (1 516 , 1 684) 
 >75 years 439 (10.9%) 6 321 (5 587 , 7 055) 
 
1 320 (1 195 , 1 444) 
 Gender 
     Male 2 505 (62.3%) 5 200 (4 878 , 5 522) 0.428 1 647 (1 595 , 1 699) 0.696 
Female 1 513 (37.7%) 4 998 (4 633 , 5 362) 
 
1 664 (1 596 , 1 732) 
 Death 
     No  3 709 (92.3%) 4 755 (4 514 , 4 996) <0.0005* 1 694 (1 651 , 1 738) <0.0005 
Yes 309 (7.7%) 9 553 (8 380 , 10 725) 
 
1 158 (1 022 , 1 294) 
 Transplant 
     No  3 643 (90.7%) 5 275 (5 010 , 5 540) <0.0005* 1 707 (1 663 , 1 751) <0.0005* 
Yes 375 (9.3%) 3 659 (3 316 , 4001) 
 
1 130 (1 033 , 1 226) 
 Recovered renal function 
No  3934 (97.9%) 5 158 (4 911 , 5 405) 0.060 1 673 (1 631 , 1 714) <0.0005* 
Yes 84 (2.1%) 3 528 (2 307 , 4 748) 
 
745 (517 , 972) 
 Myocardial infarction 
No  3 608 (90.8%) 5 057 (4 804 , 5 310) 0.021* 1 666 (1 622 , 1 710) 0.466 
Yes 367 (9.2%) 6 191 (5 261 , 7 120) 
 
1 613 (1 492 , 1 734) 
 Congestive heart failure 
No  3 577 (90.0%) 4 963 (4 704 , 5 221) <0.0005* 1 652 (1 609 , 1 695) 0.269* 
Yes 398 (10.0%) 6 951 (6 202 , 7 670) 
 
1 743 (1 587 , 1 899) 
 Peripheral vascular disease 
No  3 656 (92.0%) 5 063 (4 806 , 5 320)  0.008 1 647 (1 604 , 1 689) 0.046* 
Yes 319 (8.0%) 6 292 (5 500 , 7 084) 
 
1 828 (1 655 , 2001) 
 Cerebrovascular disease 
No  3 740 (94.1%) 5 043 (4 799 , 5 288) 0.006* 1 648 (1 605 , 1 690) 0.028* 
Yes 235 (5.9%) 7 044 (5 631 , 8 458) 
 
1 873 (1 677 , 2 070) 
 Pulmonary disease 
     No  3605 (90.7%) 5 026 (4 770 , 5 282) 0.001* 1 647 (1 604 , 1 691) 0.054* 
Yes 370 (9.3%) 6 480 (5 641 , 7 319) 
 
1 798 (1 651 , 1 945) 
 Liver disease 
     No  3 957 (99.6%) 5 152 (4 907 , 5 398) 0.275 1 661 (1 619 , 1 703) 0.794 
Yes 18 (0.4%) 7 187 (3 361 , 10 743) 
 
1 743 (812 , 2 674) 
 Diabetes 
     No  2 829 (71.2%) 4 492 (4 215 , 4 770) <0.0005* 1 798 (1 453 , 1 543) <0.0005* 
Yes 1 146 (28.8%) 6 814 (6 321 , 7 307) 
 
2 064 (1 976 , 2 152) 
 Cancer 
     No  3 810 (95.9%) 5 160 (4 907 , 5 413) 0.944 1 663 (1 621 , 1 706) 0.644 
Yes 165 (4.1%) 5 204 (4 288 , 6 120) 
 
1 614 (1 432 , 1 796) 
 Hypertension 
     No  1 986 (50.0%) 5 200 (4 840 , 5 561) 0.757 1 720 (1 659 , 1 782) 0.005* 
Yes 1 989 (50.0%) 5 123 (4 790 , 5 456) 
 
1 602 (1 546 , 1 658) 
 *Unequal variances 
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Table 1c Transplant patient characteristics and mean inpatient and outpatient costs (excluding the 
costs of transplant surgery) during the first year of renal replacement therapy 
 
n (%) 
Mean inpatient cost 
(£) (95% CI) 
P 
Mean outpatient cost (£)  
(95% CI) 
P 
Age group 
     
< 35 years 1 026 (25%)  3 941 (3 580 , 4 302) <0.0005  4 111 (3 978 , 4 246) 0.914 
36 - 45 years 1 110 (27%)  3 915 (3 568 , 4 263) 
 
 4 125 (3 996 , 4 254) 
 
46 - 55 years 973 (23%)  4 087 (3 716 , 4 458) 
 
 4 086 (3 948 , 4 224) 
 
> 55 years 1 040 (25%)  4 987 (4 628 , 5 346) 
 
 4 061 (3 928 , 4 195) 
 
Gender 
     
Male 2 589 (62.4%)  4 129 (3 908 , 4 350)  0.161*  4 073 (3 988 , 4 158) 0.373 
Female 1 560 (37.6%)  4 400 (4 092 , 4 707) 
 
 4 136 (4 027 , 4 244) 
 
Donor type  
Deceased 2 660 (64.1%)  4 540 (4 306 , 4 774) <0.0005*  4 095 (4 015 , 4 176) 0.131* 
Living 1 367 (32.9%)  3 646 (3 373 , 3 919) 
 
 4 208 (4 086 , 4 331) 
 
Death 
     
No  4020 (96.9%)  4 160 (3 981 , 4 339) 0.004*  4 175 (4 108 , 4 241)  <0.0005 
Yes 129 (3.1%)  6 424 (4 906 , 7 942) 
 
 1 657 (1 292 , 2 023) 
 
Graft failure 
     
No  3 874 (93%)   4 211 (4 027 , 4 395) 0.484*  4 279 (4 213 , 4 345) <0.0005 
Yes 275 (7%)  4 508 (3 695 , 5 321) 
 
 1 526 (1 294 , 1 758) 
 
Myocardial infarction 
     
No  3 758 (91.0%)  4 015 (3 834 , 4 195) <0.0005*  4 110 (4 040 , 4 179) 0.637* 
Yes 370 (9.0%)  6 666 (5 859 , 7 472) 
 
 4 170 (3 930 , 4 409) 
 
Congestive heart failure 
No  3 836 (93.9%)  4 051 (3 872 , 4 231) <0.0005*  4 094 (4 026 , 4 163) 0.051* 
Yes 292 (7.1%)  6 892 (5 952 , 7 832) 
 
 4 385 (4 101 , 4 669) 
 
Peripheral vascular disease 
No  3 625 (87.8%)  3 862 (3 683 , 4 040) <0.0005*  4 070 (4 000 , 4 139) 0.001* 
Yes 503 (12.2%)  7 067 (6 372 , 7 762) 
 
 4 443 (4 230 , 4 655) 
 
Cerebrovascular disease 
No  3 848 (93.2%)  4 082 (3 905 , 4 258) <0.0005*  4 110 (4 041 , 4 179) 0.552 
Yes 280 (6.8%)  6 597 (5 534 , 7 661) 
 
 4 190 (3 937 , 4 443) 
 
Pulmonary disease 
     
No  3 562 (86.3%)  4 194 (4 002 , 4 385) 0.112  4 114 (4 042 , 4 186) 0.962 
Yes 566 (13.7%)  4 620 (4 087 , 5 153) 
 
 4 119 (3 946 , 4 292) 
 
Liver disease 
     
No  4 088 (99.0%)  4 220 (4 040 , 4400) 0.024*  4 115 (4 049 , 4 182) 0.919* 
Yes 40 (1.0%)  7 530 (4 677 , 10 384) 
 
 4 068 (3 143 , 4 994) 
 
Diabetes 
     
No  3 002 (72.7%)  3 626 (3 439 , 3 813) <0.0005*  3 963 (3 890 , 4 036) <0.0005* 
Yes 1 126 (27.3%)  5 921 (5 499 , 6 343) 
 
 4 520 (4 376 , 4 665) 
 
Cancer 
     
No  3 960 (95.9%)  4 255 (4 070 , 4441) 0.866  4 111 (4 043 , 4 179) 0.553 
Yes 168 (4.1%) 4 176 (3 381 , 4 972) 
 
 4 213 (3 876 , 4 550) 
 
Hypertension 
     
No  1 003 (24.3%)  3 300 (3 021 , 3 579) <0.0005*  3 845 (3 722 , 3 968) <0.0005* 
Yes 3 125 (75.7%)  4 558 (4 338 , 4 778) 
 
 4 202 (4 123 , 4 280) 
 
*Unequal variances 
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Table 2 Mean annual hospital costs by modality and number of years on renal replacement therapy 
(excluding the costs of maintenance dialysis and transplant surgery) 
Haemodialysis patients 
Year n 
Inpatient cost (£) 
Mean (SE) 
Outpatient cost (£)  
Mean (SE) 
Total inpatient and outpatient cost (£) 
Mean (SE) 
1 12,068  7 240 (114)  1 163 (12)  8 403 (116)  
2 9,096  5 340 (95)  1 044 (13)  6 384 (98) 
3 7,614  4 844 (93)  1 069 (15)  5 913 (96) 
4 4,830  5 020 (105)  1 070 (20)  6 090 (111) 
5 2,452  5 325 (169)  1 091 (27)  6 416 (176) 
6 846  4 866 (231)  1 218 (62)  6 084 (248) 
Peritoneal dialysis patients 
Year n 
Inpatient cost (£) 
Mean (SE) 
Outpatient cost (£) 
Mean (SE) 
Total inpatient and outpatient cost (£) 
Mean (SE) 
1 4,018  5 124 (124)  1 653 (21)  6 777 (129) 
2 2,897  4 140 (118)  1 407 (23)  5 547 (125) 
3 1,934  4 198 (147)  1 514 (30)  5 712 (157) 
4 1,000 4 830 (259)  1 541 (46)  6 371 (274) 
5 440 4 433 (329)  1 510 (72)  5 943 (358) 
6 137  4 859 (541)  1 484 (143)  6 343 (609) 
Transplant patients 
Year n 
Inpatient cost (£) 
Mean (SE) 
Outpatient cost (£) 
Mean (SE) 
Total inpatient and outpatient cost (£) 
Mean (SE) 
1 4 149  4 231 (92)  4 097 (34)  8 327 (106) 
2 3 136  1 695 (77)  1 662 (21)  3 357 (88) 
3 2 307  1 334 (65)  1 403 (22)  2 738 (77) 
4 1 447  1 209 (77)  1 308 (27)  2 517 (91) 
5 759  1 368 (130)  1 234 (36)  2 603 (148) 
6 271  1 145 (205)  1 152 (53)  2 296 (225) 
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Table 3 Comparison of predicted inpatient and outpatient costs and renal replacement therapy costs by treatment modality over a four-year period for three 
hypothetical patients  
Patient 1: 25-year-old female patient with no comorbidities 
  Haemodialysis (HD)  
Peritoneal dialysis (PD) 
 
Transplant (TX) 
  
Cost of 
HD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined HD 
and hospital 
costs (£) 
 
Cost of 
PD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined PD 
and hospital 
costs (£) 
 
Cost of TX 
surgery 
(£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined TX 
and hospital 
costs (£) 
Year 1 24 804 6 204 1 295 32 303 
 
20 440 4 250 1 745 26 435 
 
14 832 3 452 4 019 22 302 
Year 2 24 804 4 335 1 148 30 287 
 
20 440 3 190 1 481 25 112 
 
0 1 206 1 472 2 678 
Year 3 24 804 3 750 1 162 29 716 
 
20 440 3 223 1 626 25 289 
 
0  995 1 228 2 223 
Year 4 24 804 3 699 1 202 29 705 
 
20 440 3 417 1 673 25 530 
 
0 908 1 139 2 047 
Total 99 216 17 989 4 807 122 011   81 760 14 080 6 526 102 366   14 832 6 561 7 858 29 251 
 
Patient 2: 50-year-old male patient with diabetes 
 
Haemodialysis (HD) 
 
Peritoneal dialysis (PD) 
 
Transplant (TX) 
 
Cost of 
HD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined HD 
and hospital 
costs (£) 
 
Cost of 
PD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined PD 
and hospital 
costs (£) 
 
Cost of TX 
surgery 
(£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined TX 
and hospital 
costs (£) 
Year 1 24 804 6 739 1 504 33 047  20 440 5 677 2 140 28 257  14 832 3 637 4 319 22 788 
Year 2 24 804 4 811 1 359 30 974  20 440 4 463 1 877 26 780  0 1 223 1 770 2 993 
Year 3 24 804 4 197 1 379 30 380  20 440 4 501 2 022 26 963  0 1 013 1 526 2 539 
Year 4 24 804 4 144 1 422 30 370  20 440 4 703 2 070 27 213  0  940 1 437 2 377 
Total 99 216 19 891 5 664 124 771   81 760 19 344 8 109 109 213   14 832 6 813 9 052 30 697 
 
Patient 3: 65-year-old male patient with peripheral vascular disease 
  Haemodialysis (HD)  
Peritoneal dialysis (PD) 
 
Transplant (TX) 
  
Cost of 
HD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined HD 
and hospital 
costs (£) 
 
Cost of 
PD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined PD 
and hospital 
costs (£) 
 
Cost of TX 
surgery 
(£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined 
TX and 
hospital 
costs (£) 
Year 1 24 804 6 512 1 249 32 564  20 440 4 174 1 719 26 333  14 832 4 263 4 008 23 103 
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Year 2 24 804 4 627 1 104 30 535  20 440 3 113 1 454 25 007  0 1 498 1 461 2 959 
Year 3 24 804 4 034 1 121 29 960  20 440 3 145 1 598 25 183  0 1 104 1 216 2 320 
Year 4 24 804 3 980 1 163 29 947  20 440 3 330 1 645 25 415  0 1 045 1 127 2 172 
Total 99 216 19 154 4 636 123 006   81 760 13 762 6 417 101 938   14 832 7 910 7 812 30 554 
 
*Fixed costs for renal replacement therapy were estimated using the following assumptions and sources: 
Haemodialysis: 2011-12 PbR tariff (HRG code LD06A = £159 per session) for satellite haemodialysis with access via arteriovenous fistula or graft 19 years and over = £159 x 3 times per week 
x 52 weeks = £ 24 804 per year 
Peritoneal dialysis:  2011-12 PbR tariff (HRG code LD12A = £56 per day) for automated peritoneal dialysis 19 years and over = £56 x 365 days = £ 20 440 per year 
Transplant surgery: NHS Reference Costs Spell Schedule 2011-12 (currency code LA02A) for kidney transplant, 19 years and over, from cadaver heart-beating donor = £ 14 832 
 
